Capital Fund Management S.A. Purchases New Shares in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Capital Fund Management S.A. acquired a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report) in the 4th quarter, Holdings Channel reports. The firm acquired 75,696 shares of the biotechnology company’s stock, valued at approximately $7,299,000.

Several other institutional investors and hedge funds have also recently modified their holdings of SRPT. Vanguard Capital Wealth Advisors raised its stake in Sarepta Therapeutics by 3.8% in the fourth quarter. Vanguard Capital Wealth Advisors now owns 2,450 shares of the biotechnology company’s stock worth $236,000 after buying an additional 90 shares in the last quarter. Cary Street Partners Investment Advisory LLC lifted its stake in shares of Sarepta Therapeutics by 154.0% in the 3rd quarter. Cary Street Partners Investment Advisory LLC now owns 254 shares of the biotechnology company’s stock valued at $31,000 after purchasing an additional 154 shares during the period. Natixis Advisors L.P. boosted its position in shares of Sarepta Therapeutics by 0.6% during the third quarter. Natixis Advisors L.P. now owns 26,026 shares of the biotechnology company’s stock valued at $3,155,000 after purchasing an additional 160 shares in the last quarter. New York Life Investment Management LLC grew its stake in Sarepta Therapeutics by 1.7% in the fourth quarter. New York Life Investment Management LLC now owns 9,942 shares of the biotechnology company’s stock worth $959,000 after purchasing an additional 166 shares during the period. Finally, LGL Partners LLC raised its holdings in Sarepta Therapeutics by 4.6% in the third quarter. LGL Partners LLC now owns 4,196 shares of the biotechnology company’s stock worth $509,000 after purchasing an additional 186 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of brokerages have recently commented on SRPT. Evercore ISI boosted their target price on shares of Sarepta Therapeutics from $108.00 to $138.00 and gave the company an “in-line” rating in a report on Tuesday, February 20th. JPMorgan Chase & Co. cut their price objective on shares of Sarepta Therapeutics from $177.00 to $175.00 and set an “overweight” rating on the stock in a report on Friday, May 3rd. UBS Group raised their target price on shares of Sarepta Therapeutics from $164.00 to $167.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Barclays boosted their price target on Sarepta Therapeutics from $141.00 to $185.00 and gave the stock an “overweight” rating in a research report on Thursday, February 29th. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and set a $128.00 price objective on shares of Sarepta Therapeutics in a research report on Thursday, May 2nd. Four equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $164.00.

Read Our Latest Stock Report on SRPT

Sarepta Therapeutics Stock Performance

Shares of NASDAQ SRPT opened at $122.59 on Tuesday. The company has a quick ratio of 3.44, a current ratio of 4.05 and a debt-to-equity ratio of 1.18. The firm’s 50-day moving average price is $125.83 and its 200-day moving average price is $117.30. Sarepta Therapeutics, Inc. has a 52-week low of $55.25 and a 52-week high of $146.68. The company has a market cap of $11.59 billion, a PE ratio of 1,114.45 and a beta of 0.96.

Sarepta Therapeutics (NASDAQ:SRPTGet Free Report) last posted its earnings results on Wednesday, May 1st. The biotechnology company reported $0.73 EPS for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.84. The business had revenue of $413.50 million during the quarter, compared to the consensus estimate of $375.52 million. Sarepta Therapeutics had a net margin of 1.20% and a return on equity of 2.20%. The firm’s revenue was up 63.1% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.44) EPS. As a group, analysts anticipate that Sarepta Therapeutics, Inc. will post 2.99 EPS for the current year.

Insider Buying and Selling

In other news, insider Dallan Murray sold 3,635 shares of the stock in a transaction that occurred on Thursday, May 2nd. The shares were sold at an average price of $140.00, for a total value of $508,900.00. Following the transaction, the insider now owns 18,125 shares in the company, valued at approximately $2,537,500. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 7.70% of the stock is currently owned by corporate insiders.

About Sarepta Therapeutics

(Free Report)

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.

Featured Articles

Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics, Inc. (NASDAQ:SRPTFree Report).

Institutional Ownership by Quarter for Sarepta Therapeutics (NASDAQ:SRPT)

Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.